A molecular atlas of innate immunity to adjuvanted and live attenuated vaccines, in mice

© 2022. The Author(s)..

Adjuvants hold great potential in enhancing vaccine efficacy, making the understanding and improving of adjuvants critical goals in vaccinology. The TLR7/8 agonist, 3M-052, induces long-lived humoral immunity in non-human primates and is currently being evaluated in human clinical trials. However, the innate mechanisms of 3M-052 have not been fully characterized. Here, we perform flow cytometry, single cell RNA-seq and ATAC-seq to profile the kinetics, transcriptomics and epigenomics of innate immune cells in murine draining lymph nodes following 3M-052-Alum/Ovalbumin immunization. We find that 3M-052-Alum/OVA induces a robust antiviral and interferon gene program, similar to the yellow fever vaccine, which is known to confer long-lasting protection. Activation of myeloid cells in dLNs persists through day 28 and single cell analysis reveals putative TF-gene regulatory programs in distinct myeloid cells and heterogeneity of monocytes. This study provides a comprehensive characterization of the transcriptomics and epigenomics of innate populations in the dLNs after vaccination.

Medienart:

E-Artikel

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Zur Gesamtaufnahme - volume:13

Enthalten in:

Nature communications - 13(2022), 1 vom: 27. Jan., Seite 549

Sprache:

Englisch

Beteiligte Personen:

Lee, Audrey [VerfasserIn]
Scott, Madeleine K D [VerfasserIn]
Wimmers, Florian [VerfasserIn]
Arunachalam, Prabhu S [VerfasserIn]
Luo, Wei [VerfasserIn]
Fox, Christopher B [VerfasserIn]
Tomai, Mark [VerfasserIn]
Khatri, Purvesh [VerfasserIn]
Pulendran, Bali [VerfasserIn]

Links:

Volltext

Themen:

9006-59-1
Adjuvants, Immunologic
Alum Compounds
Antibodies, Viral
Journal Article
Membrane Glycoproteins
Ovalbumin
Ovalbumin-alum
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
TLR7 protein, human
TLR8 protein, human
TLR8 protein, mouse
Tlr7 protein, mouse
Toll-Like Receptor 7
Toll-Like Receptor 8
Vaccines, Attenuated

Anmerkungen:

Date Completed 17.02.2022

Date Revised 16.12.2022

published: Electronic

Citation Status MEDLINE

doi:

10.1038/s41467-022-28197-9

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM336214448